261 related articles for article (PubMed ID: 11814334)
1. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
Laco GS; Collins JR; Luke BT; Kroth H; Sayer JM; Jerina DM; Pommier Y
Biochemistry; 2002 Feb; 41(5):1428-35. PubMed ID: 11814334
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivatives.
Laco GS
PLoS One; 2011; 6(8):e24314. PubMed ID: 21912628
[TBL] [Abstract][Full Text] [Related]
4. Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.
Streltsov SA
J Biomol Struct Dyn; 2002 Dec; 20(3):447-54. PubMed ID: 12437383
[TBL] [Abstract][Full Text] [Related]
5. Analysis of human topoisomerase I inhibition and interaction with the cleavage site +1 deoxyguanosine, via in vitro experiments and molecular modeling studies.
Laco GS; Du W; Kohlhagen G; Sayer JM; Jerina DM; Burke TG; Curran DP; Pommier Y
Bioorg Med Chem; 2004 Oct; 12(19):5225-35. PubMed ID: 15351405
[TBL] [Abstract][Full Text] [Related]
6. An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes.
Xiao X; Cushman M
J Am Chem Soc; 2005 Jul; 127(28):9960-1. PubMed ID: 16011334
[TBL] [Abstract][Full Text] [Related]
7. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites.
Pommier Y; Kohlhagen G; Kohn KW; Leteurtre F; Wani MC; Wall ME
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8861-5. PubMed ID: 7568032
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships.
Marco E; Laine W; Tardy C; Lansiaux A; Iwao M; Ishibashi F; Bailly C; Gago F
J Med Chem; 2005 Jun; 48(11):3796-807. PubMed ID: 15916431
[TBL] [Abstract][Full Text] [Related]
9. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
[TBL] [Abstract][Full Text] [Related]
10. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
[TBL] [Abstract][Full Text] [Related]
11. Effect of E-ring modifications in camptothecin on topoisomerase I inhibition: a quantum mechanics treatment.
Xiao X; Cushman M
J Org Chem; 2005 Nov; 70(23):9584-7. PubMed ID: 16268636
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking approach on the Topoisomerase I inhibitors series included in the NCI anti-cancer agents mechanism database.
Lauria A; Ippolito M; Almerico AM
J Mol Model; 2007 Mar; 13(3):393-400. PubMed ID: 17072654
[TBL] [Abstract][Full Text] [Related]
13. Binding mode analysis of topoisomerase inhibitors, 6-arylamino-7-chloro-quinazoline-5,8-diones, within the cleavable complex of human topoisomerase I and DNA.
Choi I; Kim C; Choi S
Arch Pharm Res; 2007 Dec; 30(12):1526-35. PubMed ID: 18254239
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of camptothecin derivatives on topoisomerase I-mediated DNA structure modification.
Wang X; Wang LK; Kingsbury WD; Johnson RK; Hecht SM
Biochemistry; 1998 Jun; 37(26):9399-408. PubMed ID: 9649322
[TBL] [Abstract][Full Text] [Related]
15. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
[TBL] [Abstract][Full Text] [Related]
16. Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA.
Chourpa I; Riou JF; Millot JM; Pommier Y; Manfait M
Biochemistry; 1998 May; 37(20):7284-91. PubMed ID: 9585542
[TBL] [Abstract][Full Text] [Related]
17. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
Drwal MN; Agama K; Wakelin LP; Pommier Y; Griffith R
PLoS One; 2011; 6(9):e25150. PubMed ID: 21966440
[TBL] [Abstract][Full Text] [Related]
18. A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin.
Kerrigan JE; Pilch DS
Biochemistry; 2001 Aug; 40(33):9792-8. PubMed ID: 11502172
[TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.
Wright CM; van der Merwe M; DeBrot AH; Bjornsti MA
J Biol Chem; 2015 May; 290(19):12068-78. PubMed ID: 25795777
[TBL] [Abstract][Full Text] [Related]
20. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.
Fiorani P; Amatruda JF; Silvestri A; Butler RH; Bjornsti MA; Benedetti P
Mol Pharmacol; 1999 Dec; 56(6):1105-15. PubMed ID: 10570037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
